Urticaria and аnaphylaxis after vaccination against COVID-19
General Medicine, 2023, 25(2), 12-18.
L. Terziev1, V. Tsvetkova2, K. Terzieva3, I. Stoilova4, V. Vicheva5
1 Department of Clinical Laboratory, Clinical Immunology and Allergology, MU – Pleven
2 Department of Dermatology, Venereology and Allergology, MU – Pleven
3 Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, MU ‒ Pleven
4 Department of Hygiene, Medical Ecology, Occupational Diseases and Disaster Medicine, MU – Pleven
5 Department of Epidemiology and Hygiene, Section Epidemiology, MU ‒ Sofia
Abstract. The study includes 10 931 persons who were vaccinated against COVID-19 in the vaccine office of UMHAT “Dr. G. Stranski” including the period December 27, 2020, to December 23, 2021. Of these, 456 reported concomitant allergic diseases, and 10 475 had no history of such. Patients with history of atopy presented with the following diseases: bronchial asthma, allergic rhinitis, urticaria/angioedema, contact dermatitis, atopic dermatitis, insect allergy, food and drug allergy. The following vaccines were administered: Pfizer BioNTech ‒ 5983, Janssen ‒ 2916, Astra Zeneca ‒ 1184, and Moderna ‒ 884. Individuals with allergy history received a three day preliminary treatment with antihistamines third generation and/or H1 + H2 blockers. None of them experienced adverse reactions. The 2 reported severe adverse reactions, anaphylaxis and severe urticaria, were in the group of subjects without history for allergies. Both cases were after administration of the first dose of vector vaccine.
Key words: COVID-19, BNT162b2 mRNA (Pfizer BioNTech), Moderna mRNA-1273, Ad26COV2-S (Janssen-Johnson), ChAdOx1-S (Astra Zeneca), severe adverse effects, аnaphylaxis, uricaria
Address for correspondence: Assoc. Prof. L. Terziev, MD, e-mail: l.terziev@abv.bg